ANG Lifesciences India Ltd.
Snapshot View

123.75 +5.85 ▲5.0%

25 November 2022, 04:01:00 PM
Volume: 40,508

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.anglifesciences.com
Market Cap 160.36 Cr.
Enterprise Value(EV) 227.88 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 9.76 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 12.68 Trailing Twelve Months Ending 2022-09
Industry PE 35.02 Trailing Twelve Months Ending 2022-09
Book Value / Share 70.03 Trailing Twelve Months Ending 2022-09
Price to Book Value 1.77 Calculated using Price: 123.75
Dividend Yield 0.65 Period Ending 2022-03
No. of Shares Subscribed 1.30 Cr. 12,958,287 Shares
FaceValue 10
Company Profile
The company is ISO-9001:2008 certified and has the modern & sophisticated plant, equipments, technique and manpower. The planning and construction of plant has been done to conform to the regulatory requirements as per the norms of WHO G.M.P. and G.L.P. as per schedule-M (revised). They manufacture their products in compliance with GMP requirements. They have dedicated area, machinery, facilities and advanced equipments for manufacturing of B-Lactum & Non-B Lactum products as per GMP Norms. The production block provides appropriate personnel and material flow. As per GMP norms, all the production processes are documented and validated to establish the accuracy of the procedures and the control measures. The Company's production capacity is 700 Lakhs Pcs per annum on per shift basis. Their products include sterile dry powder vials for Anti Biotics, Anti Ulcerant, Gluco corticoid and Anti inflammatory, Anti malarial and Anesthetic.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+4.96%
1 Week
+6.18%
1 Month
-14.68%
3 Month
-18.96%
6 Month
-34.20%
1 Year
-71.76%
2 Year
+303.62%
5 Year
+286.72%
10 Year
1 years 2022-03
Return on Equity (%) 48.13
Return on Capital Employed (%) 39.14
Return on Assets (%) 14.06

Balance Sheet View Details >>

Particulars 2 years 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 84 91
Non Curr. Liab. 37 30
Curr. Liab. 166 164
Minority Int.
Equity & Liab. 287 285
Non Curr. Assets 94 90
Curr. Assets 193 196
Misc. Exp. not W/O
Total Assets 287 285

Profit Loss View Details >>

Particulars 2 years 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 354 279
Other Income 1 1
Total Income 355 279
Total Expenditure -286 -239
PBIDT 69 41
Interest -9 -13
Depreciation -6 -8
Taxation -13 -7
Exceptional Items
PAT 40 13
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 40 13
Adjusted EPS 31 10

Cash Flow View Details >>

Particulars 1 years 2022-03 Rs. Cr.
Cash Fr. Operatn. 25
Cash Fr. Inv. -44
Cash Fr. Finan. 20
Net Change 0
Cash & Cash Eqvt 0

Shareholding Pattern View Details >>

9 Qtrs 2019-09 (%) 2020-03 (%) 2020-09 (%) 2021-03 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%)
Promoter 71.01 71.01 71.01 71.01 71.07 71.09 71.14 71.15 71.15
Public 28.99 28.99 28.99 28.99 28.93 28.91 28.86 28.85 28.85
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 25.29 25.29 67.54 42.25 21.11 42.20 44.88 44.88 44.88

Announcements View Details >>

Fri, 25 Nov 2022
Disclosure Of Related Party Transactions For The Half Year Ended 30Th September 2022.
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith disclosure of related party transactions on a consolidated basis for the half year ended 30th September 2022.
Thu, 17 Nov 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Newspaper publication of the Unaudited Financial Results (Consolidated & Standalone) for the quarter & half year ended on 30.09.2022
Mon, 14 Nov 2022
Board Meeting Outcome for Unaudited Financial Result (Standalone And Consolidated) For The Quarter & Half Year Ended 30Th September 2022.
The Board of Directors of the Company at its meeting held on today i.e. 14th November 2022 has inter-alia approved the Unaudited Financial Result (standalone & consolidated) for the quarter & half year ended 30th September 2022.

Technical Scans View Details >>

Fri, 25 Nov 2022
Closing Above Previous High Closing Above Previous High
Making Higher Highs for 3 days Making Higher Highs for 3 days
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 247,923.28 1,033.85 -0.1%
Cipla Ltd. 89,193.72 1,105.35 +0.9%
Divi's Laboratories Ltd. 88,708.98 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. 73,559.75 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. 68,713.97 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. 55,107.38 1,628.25 +0.8%
Abbott India Ltd. 43,050.55 20,267.50 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.40 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-09 34.75 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-09 29.59 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 23.60 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 82.06 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 69.14 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-09 48.82 20,267.50 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.67 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-09 4.07 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-09 7.30 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 3.53 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 11.51 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 9.05 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-09 15.86 20,267.50 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.02 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 0.04 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 0.00 20,267.50 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 13.10 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 29.95 20,267.50 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 13.10 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 29.95 20,267.50 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,267.50 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 798.70 20,267.50 +0.4%

FAQ's On ANG Lifesciences India Ltd.

What is ANG Lifesciences share price?

Can I buy ANG Lifesciences shares now?

What is the Dividend Yield of ANG Lifesciences?

What is the Market Cap of ANG Lifesciences?

What are the key metrics to analyse ANG Lifesciences?

What is the 52 Week High and Low of ANG Lifesciences?

What is the trend of ANG Lifesciences share price?